Novartis Q2 Earnings Beat on Strong Sales of Cancer and MS Drugs
Novartis reported better-than-expected second-quarter earnings for 2026, driven by strong sales in its cancer and multiple sclerosis drug portfolios. Despite a significant drop in revenue from its top-selling heart failure medication Entresto due to generic competition, the company's core operating income met forecasts.
Tickers: $NVS
Topics: cancer treatments drug sales growth earnings multiple sclerosis